United Kingdom

People: Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

23 Apr 2019
Change (% chg)

$-0.37 (-2.54%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Herman, Alan 

Dr. Alan C. Herman, Ph.D., is Chief Scientific Officer of the Coherus BioSciences, Inc. Dr. Herman previously founded and served as Chief Executive Officer of WindRose Analytica, Inc., a contract analytical laboratory. In May 2009, WindRose Analytica was acquired by Althea Technologies, Inc., a biologic manufacturing company. Dr. Herman served as Chief Scientific Officer and Vice President of Product Development at Althea Technologies from May 2009 to April 2011. Prior to that, Dr. Herman served as Senior Director of Quality Control for Tercica, Inc., a biopharmaceutical company. In 1989, Dr. Herman joined Amgen where he started and served in the Analytical Research and Development Department until May 2009. In 1984, he joined Genentech where he worked first in process development and later in pharmaceutics. During his time at Genentech, Dr. Herman worked on a number of products, including human growth hormone, tissue plasminogen activator and interferon. Dr. Herman started his career at Merck, where he worked on a recombinant hepatitis B vaccine. Dr. Herman received his B.S. and M.S. degrees in Biology at Indiana University of Pennsylvania. He received a Ph.D. in Microbiology from Duke University and did his post-doctoral work in oncogenic virus structure at Duke University Medical Center under Dr. Dani Bolognesi.

Basic Compensation

Total Annual Compensation, USD 352,510
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 835,642
Fiscal Year Total, USD 1,188,150

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 72,664 1,991,880.00
Name Fiscal Year Total

Dennis Lanfear


Jean-Frederic Viret


Peter Watler


Alan Herman


Vincent Anicetti


Barbara Finck

As Of  31 Dec 2017